

DORSET MEDICINES ADVISORY GROUP

COMMISSIONING STATEMENT ON THE USE OF BRODALUMAB (KYNTHEUM®) FOR TREATING MODERATE TO SEVERE PLAQUE PSORIASIS (NICE TA511)

SUMMARY	
<ul style="list-style-type: none"> NHS Dorset Clinical Commissioning Group supports the use of brodalumab (Kyntheum®) for treating moderate to severe plaque psoriasis within NICE TA511. 	
BACKGROUND	<p>Brodalumab is a recombinant human monoclonal antibody that binds with high affinity to interleukin-17RA and blocks the activity of pro-inflammatory cytokines.</p>
RELEVANT NICE GUIDANCE	<p>Brodalumab is recommended as an option for treating plaque psoriasis in adults, only if:</p> <ul style="list-style-type: none"> the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and the disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated and the company provides the drug with the discount agreed in the patient access scheme. <p>Stop brodalumab at 12 weeks if the psoriasis has not responded adequately, defined as:</p> <ul style="list-style-type: none"> a 75% reduction in the PASI score (PASI 75) from when treatment started or a 50% reduction in the PASI score (PASI 50) and a 5-point reduction in DLQI from when treatment started. <p>When using the PASI, healthcare professionals should take into account skin colour and how this could affect the PASI score, and make the clinical adjustments they consider appropriate.</p> <p>When using the DLQI, healthcare professionals should take into account any physical, psychological, sensory or learning disabilities, or communication difficulties that could affect the responses to the DLQI and make any adjustments they consider appropriate.</p> <p>These recommendations are not intended to affect treatment with brodalumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.</p>
FORMULARY STATUS	Red
PBR STATUS	Excluded from PbR tariff
COMMISSIONING IMPLICATIONS	Represents an additional option for this stage of management. Where clinically a range of biologics are an option for a patient the most cost-effective one should be selected.

DORSET MEDICINES ADVISORY GROUP

RELEVANT CLINICAL WORKING GROUP	Commissioned within the elective care workstream of the CCG.
PATIENT PATHWAY IMPLICATIONS	<p>The marketing authorisation for brodalumab is for 'adults who are candidates for systemic therapy'. However, the manufacturer positioned brodalumab fourth line, as an alternative to biological therapies, apremilast and dimethyl fumarate.</p> <p>One NICE clinical expert confirmed that this is the stage in therapy at which NHS clinicians would most likely use brodalumab. The NICE committee concluded that it would appraise brodalumab as a fourth-line therapy, which is when other biological therapies, apremilast and dimethyl fumarate are current treatment options.</p>
SUMMARY OF EVIDENCE TO SUPPORT FORMULARY STATUS	<p>From NICE TA511:</p> <p>Clinical trial results show that brodalumab improves severe psoriasis more than placebo and ustekinumab. When compared indirectly, it appears to be as effective as other anti-interleukin-17 agents. Cost-effectiveness estimates for brodalumab compared with other biological treatments, and with apremilast and dimethyl fumarate, show that it is generally more cost effective (that is, depending on the comparator, it costs less but is more effective, or costs more but is considerably more effective). Brodalumab can be offered as an option to people with severe psoriasis that has not responded to other systemic non-biological therapies.</p>
ASSESSMENT OF COST IMPLICATIONS	<p>Brodalumab is administered by subcutaneous injection.</p> <p>Brodalumab costs £1,280 per pack of 2 syringes of 210 mg/1.5 ml solution.</p> <p>Annual cost of treatment = £17,420</p> <p>The company has agreed a patient access scheme with the Department of Health. This scheme provides a simple discount to the list price of brodalumab, with the discount applied at the point of purchase or invoice. The level of the discount is commercial in confidence. The Department of Health considered that this patient access scheme does not constitute an excessive administrative burden on the NHS.</p>
REFERENCES	<p>NICE TA511 – Brodalumab for moderate to severe plaque psoriasis</p> <p>KYNTHEUM® summary of product characteristics (accessed 16/10/2017)</p> <p>BNF online (accessed 16/10/2017)</p>
Date	April 2018
Review date	May 2020 or before, in the light of new information
Contact for this Policy	Michelle Trevett, Senior Pharmacist, NHS Dorset CCG